Simplifying Global Compliance
GSK Sues Apotex to Protect Enlarged Prostate Drug Avodart
Washington Drug Letter
GlaxoSmithKline (GSK) is suing Apotex, saying the generic maker’s proposed version of enlarged prostate drug Avodart would infringe on a GSK patent and should be prohibited from the U.S. market until the patent expires in late 2015.
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing